TY - JOUR
T1 - Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment
T2 - Performance of dilute Russell viper venom test and silica clotting time in comparison with Staclot® LA
AU - Tripodi, Armando
AU - Chantarangkul, Veena
AU - Clerici, Marigrazia
AU - Mannucci, Pier Mannuccio
PY - 2002/10/1
Y1 - 2002/10/1
N2 - The detection of lupus anticoagulant (LA) in plasmas from patients on oral anticoagulants is problematic because of their prolonged clotting times. Mixing of patients and normal plasmas prior to testing for LA is employed to overcome this problem. We investigated the diagnostic efficacy of silica clotting time (SCT) and dilute Russell viper venom test (dRVVT) performed at low and high phospholipid concentrations, to diagnose LA in patients on oral anticoagulants, in comparison with Staclot® LA (Stago) performed with and without hexagonal phospholipids and normal plasma. Case materials were 114 filtered plasmas from patients on oral anticoagulants with (n = 62) and without (n = 52) the antiphospholipid syndrome. Plasmas were considered LA-positive when Staclot® LA (taken as the "gold standard") was diagnostic for LA. Forty-four plasmas were positive with Staclot® LA. Forty and 39 of these were also positive with SCT and dRVVT (sensitivity relative to Staclot® LA was 91% and 89%, respectively). Seventy plasmas were negative with Staclot® LA. Three of these were positive with both SCT and dRVVT (specificity relative to Staclot® LA was 96%). Kappa values for measure of agreement were 0.87 and 0.85 (p
AB - The detection of lupus anticoagulant (LA) in plasmas from patients on oral anticoagulants is problematic because of their prolonged clotting times. Mixing of patients and normal plasmas prior to testing for LA is employed to overcome this problem. We investigated the diagnostic efficacy of silica clotting time (SCT) and dilute Russell viper venom test (dRVVT) performed at low and high phospholipid concentrations, to diagnose LA in patients on oral anticoagulants, in comparison with Staclot® LA (Stago) performed with and without hexagonal phospholipids and normal plasma. Case materials were 114 filtered plasmas from patients on oral anticoagulants with (n = 62) and without (n = 52) the antiphospholipid syndrome. Plasmas were considered LA-positive when Staclot® LA (taken as the "gold standard") was diagnostic for LA. Forty-four plasmas were positive with Staclot® LA. Forty and 39 of these were also positive with SCT and dRVVT (sensitivity relative to Staclot® LA was 91% and 89%, respectively). Seventy plasmas were negative with Staclot® LA. Three of these were positive with both SCT and dRVVT (specificity relative to Staclot® LA was 96%). Kappa values for measure of agreement were 0.87 and 0.85 (p
KW - Lupus anticoagulant
KW - Oral anticoagulation
KW - Thrombosis
UR - http://www.scopus.com/inward/record.url?scp=0036796269&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036796269&partnerID=8YFLogxK
M3 - Article
C2 - 12362227
AN - SCOPUS:0036796269
SN - 0340-6245
VL - 88
SP - 583
EP - 586
JO - Thrombosis and Haemostasis
JF - Thrombosis and Haemostasis
IS - 4
ER -